400 related articles for article (PubMed ID: 29396858)
1. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
Golan T; Stossel C; Atias D; Buzhor E; Halperin S; Cohen K; Raitses-Gurevich M; Glick Y; Raskin S; Yehuda D; Feldman A; Schvimer M; Friedman E; Karni R; Wilson JM; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Gallinger S; Berger R
Int J Cancer; 2018 Jul; 143(1):179-183. PubMed ID: 29396858
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived xenograft models of BRCA-associated pancreatic cancers.
Golan T; Atias D; Stossel C; Raitses-Gurevich M
Adv Drug Deliv Rev; 2021 Apr; 171():257-265. PubMed ID: 33617901
[TBL] [Abstract][Full Text] [Related]
3. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.
Wang Y; Park JYP; Pacis A; Denroche RE; Jang GH; Zhang A; Cuggia A; Domecq C; Monlong J; Raitses-Gurevich M; Grant RC; Borgida A; Holter S; Stossel C; Bu S; Masoomian M; Lungu IM; Bartlett JMS; Wilson JM; Gao ZH; Riazalhosseini Y; Asselah J; Bouganim N; Cabrera T; Boucher LM; Valenti D; Biagi J; Greenwood CMT; Polak P; Foulkes WD; Golan T; O'Kane GM; Fischer SE; Knox JJ; Gallinger S; Zogopoulos G
Clin Cancer Res; 2020 Oct; 26(20):5462-5476. PubMed ID: 32816949
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.
Stossel C; Raitses-Gurevich M; Atias D; Beller T; Glick Gorman Y; Halperin S; Peer E; Denroche RE; Zhang A; Notta F; Wilson JM; O'Kane GM; Haimov Talmoud E; Amison N; Schvimer M; Salpeter SJ; Bar V; Zundelevich A; Tirosh I; Tal R; Dinstag G; Kinar Y; Eliezer Y; Ben-David U; Gavert NS; Straussman R; Gallinger SJ; Berger R; Golan T
Cancer Discov; 2023 Aug; 13(8):1826-1843. PubMed ID: 37449843
[TBL] [Abstract][Full Text] [Related]
5. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
6. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
[TBL] [Abstract][Full Text] [Related]
7. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
8. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
10. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
11. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
13. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.
George E; Kim H; Krepler C; Wenz B; Makvandi M; Tanyi JL; Brown E; Zhang R; Brafford P; Jean S; Mach RH; Lu Y; Mills GB; Herlyn M; Morgan M; Zhang X; Soslow R; Drapkin R; Johnson N; Zheng Y; Cotsarelis G; Nathanson KL; Simpkins F
JCI Insight; 2017 Jan; 2(1):e89760. PubMed ID: 28097235
[TBL] [Abstract][Full Text] [Related]
14. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
[TBL] [Abstract][Full Text] [Related]
15. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Sorscher S; Ramkissoon S
Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
[TBL] [Abstract][Full Text] [Related]
16. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibition in treatment of pancreatic cancer.
Hammel P; Zhang C; Matile J; Colle E; Hadj-Naceur I; Gagaille MP; Bouattour M; Cros J; de Mestier L; Lamuraglia M
Expert Rev Anticancer Ther; 2020 Nov; 20(11):939-945. PubMed ID: 32936674
[TBL] [Abstract][Full Text] [Related]
18. Emerging strategies in BRCA-positive pancreatic cancer.
Kowalewski A; Szylberg Ł; Saganek M; Napiontek W; Antosik P; Grzanka D
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1503-1507. PubMed ID: 29777302
[TBL] [Abstract][Full Text] [Related]
19. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
20. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
